🇺🇸 ARWR — Arrowhead Pharmaceuticals, Inc.

Salud Compra fuerte
← Volver

Precio actual

61,65 USD

Máx. histórico

2.925,00

12011 días

Split 1:10 del 17/11/2011

Caída desde máximo

-97,89%

Rango 52 semanas

37,06 – 95,49

Variación hoy

+3,56%

Cierre anterior

59,53

Rango de hoy

59,06 – 61,99

Volumen hoy

1.487.357

Peor caída histórica

-99,96%

16/12/1993 → 16/12/2016

Aún sin recuperar

Volatilidad anualizada ⓘ

231,86%

Información
Nombre completo
Arrowhead Pharmaceuticals, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
711
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
107,71 USD (puede no estar actualizado)
Primera cotización
16/12/1993
Precio actualizado
hace 9 horas
Sobre la empresa

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Splits Registrados en el histórico de precios
Fecha Ratio
17/11/2011 1:10
15/01/2004 1:65
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
23/01/2017 1,81 1,85 1,70 1,73 -4,95% 8,29% 864.900
20/01/2017 1,83 1,90 1,80 1,82 -1,09% 5,46% 583.900
19/01/2017 1,98 1,98 1,83 1,84 -6,12% 7,58% 765.100
18/01/2017 1,98 1,98 1,90 1,96 +0,51% 4,04% 546.100
17/01/2017 2,06 2,06 1,88 1,95 -5,34% 8,74% 1.362.600
13/01/2017 2,27 2,27 2,02 2,06 -5,07% 11,01% 1.599.700
12/01/2017 2,23 2,24 2,07 2,17 -2,69% 7,53% 2.304.200
11/01/2017 2,08 2,38 2,06 2,23 +10,40% 15,38% 4.776.600
10/01/2017 1,90 2,09 1,79 2,02 +6,88% 15,79% 2.788.600
09/01/2017 2,00 2,09 1,80 1,89 -3,57% 14,50% 2.988.900
06/01/2017 1,60 1,96 1,59 1,96 +22,50% 23,13% 4.057.200
05/01/2017 1,69 1,69 1,58 1,60 -5,33% 6,51% 663.300
04/01/2017 1,69 1,75 1,61 1,69 +0,60% 8,28% 1.886.000
03/01/2017 1,56 1,69 1,42 1,68 +8,39% 17,31% 2.106.500
30/12/2016 1,69 1,73 1,53 1,55 -6,06% 11,83% 2.667.100
29/12/2016 1,53 1,66 1,50 1,65 +6,45% 10,46% 2.216.300
28/12/2016 1,52 1,57 1,49 1,55 +1,31% 5,26% 1.310.500
27/12/2016 1,59 1,63 1,44 1,53 -3,77% 12,26% 2.905.200
23/12/2016 1,38 1,59 1,35 1,59 +16,06% 17,39% 4.635.700
22/12/2016 1,27 1,37 1,26 1,37 +7,87% 8,66% 2.017.500
21/12/2016 1,22 1,28 1,20 1,27 +2,42% 6,56% 1.691.800
20/12/2016 1,27 1,30 1,22 1,24 -0,80% 6,30% 2.289.800
19/12/2016 1,24 1,32 1,22 1,25 +0,81% 8,06% 1.701.500
16/12/2016 1,29 1,30 1,23 1,24 -2,36% 5,43% 2.761.900
15/12/2016 1,35 1,35 1,25 1,27 +0,00% 7,41% 1.770.500
14/12/2016 1,28 1,31 1,25 1,27 +0,00% 4,69% 1.586.300
13/12/2016 1,26 1,30 1,25 1,27 -0,78% 3,97% 1.166.000
12/12/2016 1,35 1,36 1,25 1,28 -5,19% 8,15% 2.318.600
09/12/2016 1,39 1,39 1,34 1,35 -1,46% 3,60% 1.366.400
08/12/2016 1,36 1,39 1,33 1,37 +0,00% 4,41% 1.174.300